Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.170
-0.020 (-1.68%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Marker Therapeutics Stock Forecast
MRKR's stock price has decreased by -72.08% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Marker Therapeutics stock have an average target of 13.17, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 1,025.64% from the current stock price of 1.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Marker Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| WBB Securities | WBB Securities | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +968.38% | Apr 1, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +583.76% | Mar 5, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $11 → $19 | Strong Buy | Maintains | $11 → $19 | +1,523.93% | Oct 21, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +840.17% | Apr 30, 2024 |
| Roth Capital | Roth Capital | Strong Buy → Hold Downgrades $30 → $10 | Strong Buy → Hold | Downgrades | $30 → $10 | +754.70% | Feb 17, 2022 |
Financial Forecast
Revenue This Year
3.29M
from 6.59M
Decreased by -50.11%
Revenue Next Year
1.97M
from 3.29M
Decreased by -40.18%
EPS This Year
-2.68
from -1.19
EPS Next Year
-2.89
from -2.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.1M | 6.1M | 39.9M | ||
| Avg | 3.3M | 2.0M | 38.7M | ||
| Low | n/a | n/a | 37.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.8% | 84.7% | 1,927.0% | ||
| Avg | -50.1% | -40.2% | 1,869.0% | ||
| Low | - | - | 1,791.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.35 | -0.80 | -0.29 | ||
| Avg | -2.68 | -2.89 | -1.32 | ||
| Low | -4.27 | -5.05 | -2.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.